Kiwa Bio-Tech Products Group Corporation (OTCPK:KWBT) announced that it has entered into securities purchase agreements for issuance of one convertible promissory note for $337,500 each to Labrys Fund, LP, a fund managed by The EquiLux Group, LP and TFK Investments, LLC for gross proceeds of $675,000 on February 5, 2020. Each notes will have a principal amount of $375,000 and will be issued at a discount of $37,500 at the rate of interest of 12% per annum and must be repaid on or before 180 calendar days after the funding date of each respective tranche. The notes may be prepaid at any time before maturity date without any prepayment penalty.